Home Investment Firms • Jim Tananbaum, The Healthcare Investment Capitalist

Jim Tananbaum, The Healthcare Investment Capitalist

Foresite Capital is an enterprise that was born out of the experience that spans over 25 years and realization of the fact that there was a great need to cover various gaps that had not been addressed in the healthcare sector. Jim Tananbaum who understand the various up and downs that exist in the area of health added extra effort in bringing change to the industry.

Jim Tananbaum realized that there are very many ideas that need to be incorporated into the health care sector and the significant hurdle that prevents such an achievement is the lack of adequate capital. Since the healthcare sector requires high precision, this factor translates into the capital requirement needed to satisfy the needs of the industry. Jim Tananbaum, therefore, decided to establish for site Capital, where he acts as the chief executive officer, to boost the efforts of different people who needed to make their ideas come to life and smoothen up different processes in the medical industry. Check out LinkedIn to know more.

Mind Strong Health, for instance, has been able to acquire over $14 million from Foresite Capital and other investment companies. It plans to advance its research in the general population on the various neuropsychiatric complications that affect different people. Mind Strong Health is succeeding in its quest simply by using a smartphone application that collects data based on the manner in which a particular user taps on the screen. By investing into such a great course, Jim Tananbaum ensures that more can be achieved in the medical industry.

Tananbaum has founded and co-founded various health care enterprises that deal with varying cases, and this has led him to be listed as number 52 on the Midas List. Forbes makes use of the list to outline the various capitalists in the financial markets, who advance different projects that create a significant impact on the general society.

GelTex which is a pharmaceutical company that was acquired for approximately $1.6 billion back in 1998 at a time when the original drug produced by the firm was only able to amass an annual revenue of about $200 million. Currently, Renzela can bring back annual income of about $1 billion indicating that Jim’s investments help to bring change.

See more: https://inc42.com/buzz/forbes-midas-top-100-investors-2017/